Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 (Ulotaront) in Adults With Generalized Anxiety Disorder
2022-502077-42-00Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Ulotaront with Placebo (2 arms). Primary endpoint: Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at endpoint. Started Sep 2023; status: completed.
02
Drugs
ulotaront
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2022-502077-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502077-42-00.